Why South Korea?
South Korean Life Science Industry has been rapidly
expanding, and there is a huge unmet need for partnership
for overcoming key R&D / Commercial bottlenecks.
2,500+
Biotech & Life Sciences
companies in South Korea
in 2023,
with an increasing headcount
every year.
$3.2 Bn
Gross investment made by
South Korean biotech & life
sciences companies in 2022
(in USD term).
1st Ranked
Among OECD member
countries for the highest
five-year cancer
survival rate in 2019.
Approx. 50%
YoY return on Healthcare ETF
in South Korea showing
strong growth.
Also, approx. 80% YoY return
on Biotech ETF.